Study
Early-phase study suggesting aspirin is safe and feasible for men with low-risk prostate cancer under monitoring.
In plain language
Early-phase study suggesting aspirin is safe and feasible for men with low-risk prostate cancer under monitoring. While biologically plausible, larger trials are needed to determine if it slows disease progression.
Use the full description to understand the study design, methods, and the limits of the findings.
This feasibility study examined whether low-dose aspirin and/or vitamin D3 could be safely used in men with prostate cancer under active surveillance. The intervention was well-tolerated, with good adherence and no serious safety concerns.
Open the original publication for the complete methods, outcomes, and source material.
Published December 2025
Opens at the publisher · external site · may require institutional access
The study provides initial feasibility data on the use of aspirin and vitamin D3 in older adults with prostate cancer. While it is relevant and published in a reputable journal, the study design lacks the rigor of later-phase trials, and there is limited bias control and replication data.
| Category | Score | Rating |
|---|---|---|
| Study Design / Evidence Level | 6.0/10 | |
| Bias & Methods | 5.0/10 | |
| Statistical Integrity | 6.0/10 | |
| Transparency | 7.0/10 | |
| Conflict of Interest Disclosure | 8.0/10 | |
| Replication / External Validation | 4.0/10 | |
| Relevance to Seniors | 9.0/10 | |
| Journal Quality | 7.0/10 |
The study is a preliminary investigation, and its findings should be interpreted with caution. Larger, more rigorous trials are necessary to confirm these initial findings.
Build a personalized plan using research-backed studies, conditions, and treatments.